Gilford, CT, United States of America

John L Herrmann


 

 

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 50(Granted Patents)


Location History:

  • Guilford, CT (US) (2005 - 2006)
  • Gilford, CT (US) (2003 - 2007)
  • Bothell, WA (US) (2014)

Company Filing History:


Years Active: 2003-2014

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: John L Herrmann: Innovator in Biotechnology

Introduction

John L Herrmann is a prominent inventor based in Gilford, Connecticut, known for his significant contributions to the field of biotechnology. With an impressive portfolio of seven patents, Herrmann has made substantial advancements, particularly in the development of therapeutic antibodies.

Latest Patents

Herrmann's latest innovations include a series of groundbreaking patents. One notable invention is focused on "Antibodies directed to GPNMB and uses thereof." This patent encompasses fully human monoclonal antibodies that specifically bind to GPNMB. It provides methods for producing immunoconjugates integrating anti-GPNMB antibodies. Additionally, it introduces bispecific antibodies, combining anti-GPNMB and anti-CD3 components for therapeutic applications.

Another significant patent is centered around "Polypeptides of FGF-CX." This invention highlights FGF-CX, a novel isolated polypeptide, along with polynucleotides encoding it and antibodies that bind to FGF-CX or its variants. The applications of this invention extend to the detection and treatment of various pathological states, showcasing Herrmann's innovative spirit and commitment to addressing medical challenges.

Career Highlights

Throughout his career, John L Herrmann has held pivotal roles in notable biotechnology companies, notably Curagen Corporation and Celldex Therapeutics Limited. His work at these organizations has enabled him to contribute to cutting-edge research and development in therapeutic solutions.

Collaborations

Herrmann has collaborated with esteemed coworkers, including Luca Rastelli and John R MacDougall. These partnerships fostered a rich environment for innovation and have undoubtedly enhanced the impact of their collective research efforts.

Conclusion

John L Herrmann exemplifies the essence of innovation in biotechnology. With his seven patents and key collaborations, he continues to play a vital role in advancing therapeutic solutions that hold the potential to transform medical treatments. His work not only reflects his dedication as an inventor but also significantly contributes to the broader scientific community's quest for innovative health solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…